1. Home
  2. DEI vs BLTE Comparison

DEI vs BLTE Comparison

Compare DEI & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DEI
  • BLTE
  • Stock Information
  • Founded
  • DEI 1971
  • BLTE 2018
  • Country
  • DEI United States
  • BLTE United States
  • Employees
  • DEI N/A
  • BLTE N/A
  • Industry
  • DEI Real Estate Investment Trusts
  • BLTE Biotechnology: Pharmaceutical Preparations
  • Sector
  • DEI Real Estate
  • BLTE Health Care
  • Exchange
  • DEI Nasdaq
  • BLTE Nasdaq
  • Market Cap
  • DEI 2.6B
  • BLTE 2.6B
  • IPO Year
  • DEI 2006
  • BLTE 2022
  • Fundamental
  • Price
  • DEI $12.74
  • BLTE $98.49
  • Analyst Decision
  • DEI Hold
  • BLTE Strong Buy
  • Analyst Count
  • DEI 8
  • BLTE 4
  • Target Price
  • DEI $17.86
  • BLTE $96.00
  • AVG Volume (30 Days)
  • DEI 1.9M
  • BLTE 77.5K
  • Earning Date
  • DEI 11-04-2025
  • BLTE 11-12-2025
  • Dividend Yield
  • DEI 5.97%
  • BLTE N/A
  • EPS Growth
  • DEI N/A
  • BLTE N/A
  • EPS
  • DEI 0.22
  • BLTE N/A
  • Revenue
  • DEI $1,001,173,000.00
  • BLTE N/A
  • Revenue This Year
  • DEI $2.92
  • BLTE N/A
  • Revenue Next Year
  • DEI $1.96
  • BLTE N/A
  • P/E Ratio
  • DEI $58.68
  • BLTE N/A
  • Revenue Growth
  • DEI 3.24
  • BLTE N/A
  • 52 Week Low
  • DEI $12.39
  • BLTE $49.00
  • 52 Week High
  • DEI $20.50
  • BLTE $99.00
  • Technical
  • Relative Strength Index (RSI)
  • DEI 23.29
  • BLTE 79.91
  • Support Level
  • DEI $12.59
  • BLTE $90.84
  • Resistance Level
  • DEI $13.67
  • BLTE $99.00
  • Average True Range (ATR)
  • DEI 0.31
  • BLTE 3.59
  • MACD
  • DEI -0.04
  • BLTE 0.75
  • Stochastic Oscillator
  • DEI 12.10
  • BLTE 97.49

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Share on Social Networks: